Letter: The Hawthorne effect—behavioral changes from research observation—as confounder and mediator in the ERASE trial <p>Prostate Cancer and Prostatic Diseases, Published online: 24 February 2026; <a href="https://www.nature.com/articles/s41391-026-01087-7">doi:10.1038/s41391-026-01087-7</a></p>Letter: The Hawthorne effect—behavioral changes from research observation—as confounder and mediator in the ERASE trial Prostate Cancer Journal February 24, 2026 Original source
HER2-positive gastroesophageal cancer: meaningful progress, unresolved biology KCWISE is a randomized phase III trial evaluating anbenitamab plus chemotherapy (paclitaxel, docetaxel or irinotecan) versus chemotherapy alone in trastuzumab-pretreated, HER2-positive gastric/GEJ cancer.1 Preplanned interim analysis showed a substantial improvement in progression free survival (PFS) benefit (median 7.1 versus 2.7 months; hazard ratio [HR] 0.25; p<0.0001) and a strong early overall survival (OS) signal (median 19.6 versus 11.5 months; HR,… Annals of Oncology February 23, 2026 Original source
Decoding cancer across scales with metabolomics <p>Nature Reviews Cancer, Published online: 20 February 2026; <a href="https://www.nature.com/articles/s41568-026-00908-0">doi:10.1038/s41568-026-00908-0</a></p>In this Review, Rowles and Patti present metabolomics workflows to study cancer across scales. They explore the nutrient demands of cancer cells and how those needs can be fulfilled through metabolic interactions within the tumour microenvironment or systemic crosstalk with distant tissues, and discuss the opportunities and challenges of each approach… Nature Reviews Cancer February 22, 2026 Original source
Artificial intelligence-generated synthetic data for cancer research and clinical trials <p>Nature Reviews Cancer, Published online: 20 February 2026; <a href="https://www.nature.com/articles/s41568-026-00912-4">doi:10.1038/s41568-026-00912-4</a></p>Synthetic data generated by generative artificial intelligence models can serve as a substitute for real patient data. In this Review, Eckardt et al. discuss how synthetic data sets can overcome barriers to data access and sharing, democratize scientific discovery in cancer research, and reduce the costs and failure rates of cancer… Nature Reviews Cancer February 22, 2026 Original source
Single-port transvesical enucleation of the prostate (STEP) for benign prostatic hyperplasia: a comparative analysis of patients with large (80–150cc) and very large (>150cc) prostate volumes <p>Prostate Cancer and Prostatic Diseases, Published online: 21 February 2026; <a href="https://www.nature.com/articles/s41391-026-01074-y">doi:10.1038/s41391-026-01074-y</a></p>Single-port transvesical enucleation of the prostate (STEP) for benign prostatic hyperplasia: a comparative analysis of patients with large (80–150cc) and very large (>150cc) prostate volumes Prostate Cancer Journal February 21, 2026 Original source
Modern day cost analysis demonstrates medical therapy as a highly cost‑effective first‑line treatment for BPH/LUTS <p>Prostate Cancer and Prostatic Diseases, Published online: 21 February 2026; <a href="https://www.nature.com/articles/s41391-026-01089-5">doi:10.1038/s41391-026-01089-5</a></p>Modern day cost analysis demonstrates medical therapy as a highly cost‑effective first‑line treatment for BPH/LUTS Prostate Cancer Journal February 21, 2026 Original source
Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy images <p>Leukemia, Published online: 20 February 2026; <a href="https://www.nature.com/articles/s41375-026-02893-7">doi:10.1038/s41375-026-02893-7</a></p>Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy images Leukemia Journal February 21, 2026 Original source
The FGFR1 N546K mutation confers resistance to pemigatinib in MLN-<i>ZMYM2::FGFR1</i> <p>Leukemia, Published online: 20 February 2026; <a href="https://www.nature.com/articles/s41375-026-02890-w">doi:10.1038/s41375-026-02890-w</a></p>The FGFR1 N546K mutation confers resistance to pemigatinib in MLN-<i>ZMYM2::FGFR1</i> Leukemia Journal February 21, 2026 Original source
From controversy to opportunity: experts weigh in on myeloid states as determinants in cancer immunotherapy Journal for ImmunoTherapy of Cancer February 20, 2026 Original source
Donor-derived CD19-targeted CAR-NK cells induce complete remission in a child with relapsed B-ALL after failure of blinatumomab and autologous CD19-targeted CAR-T <p>Relapse remains the primary cause of treatment failure and death in pediatric B-cell acute lymphoblastic leukemia (B-ALL). Novel therapeutic approaches are imperative for those who are refractory to blinatumomab and chimeric antigen receptor T (CAR-T) cell therapy. CAR-natural killer (NK) cells have emerged as promising candidates for novel cancer immunotherapies, with enhanced antitumor activity and low rates of adverse events.… Journal for ImmunoTherapy of Cancer February 20, 2026 Original source
QVT score, a radiomic biomarker of vascular complexity, enables prognostication and monitoring of NSCLC immunotherapy Background <p>Immune checkpoint inhibitors (ICIs) improve survival in advanced non-small cell lung cancer (NSCLC), yet current biomarkers such as programmed death-ligand 1 (PD-L1) expression and response criteria (Response Evaluation Criteria in Solid Tumors, RECIST, V.1.1) align poorly with long-term survival. Radiomics has been proposed as a source of novel biomarkers, but standard radiomic approaches suffer from limited biological interpretability and… Journal for ImmunoTherapy of Cancer February 20, 2026 Original source
Therapeutic vaccination for active induction of T cell immunity against cancer, ready for a rich harvest after 40 years <p>Therapeutic vaccines include DNA, mRNA, protein-loaded antigen-presenting cell, synthetic long peptide (SLP) and recombinant virus platforms. Only two therapeutic vaccines for neoplastic disease were approved by the Food and Drug Administration in the past 40 years: sipuleucel-T, approved in 2010 for hormone-resistant metastatic prostate cancer and targeting prostate acid phosphatase; and zopapogene imadenovec, approved in 2025 for recurrent respiratory papillomatosis,… Journal for ImmunoTherapy of Cancer February 20, 2026 Original source
Telesurgery in prostate cancer: a systematic review of clinical applications and future directions <p>Prostate Cancer and Prostatic Diseases, Published online: 20 February 2026; <a href="https://www.nature.com/articles/s41391-026-01090-y">doi:10.1038/s41391-026-01090-y</a></p>Telesurgery in prostate cancer: a systematic review of clinical applications and future directions Prostate Cancer Journal February 20, 2026 Original source
What is the Difference Between Cancer in Adults and Cancer in Children? <p>The differences between cancers in adults and children go well beyond age. In many respects, they are markedly different diseases.</p> <p>The post <a href="https://blog.dana-farber.org/insight/2026/02/difference-cancer-adults-cancer-children/">What is the Difference Between Cancer in Adults and Cancer in Children?</a> appeared first on <a href="https://blog.dana-farber.org/insight">Dana-Farber Cancer Institute</a>.</p> Dana-Farber Cancer Institute February 20, 2026 Original source
CD40/PI3K/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival <p>Leukemia, Published online: 19 February 2026; <a href="https://www.nature.com/articles/s41375-026-02894-6">doi:10.1038/s41375-026-02894-6</a></p>CD40/PI3K/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival Leukemia Journal February 19, 2026 Original source
Development of a prognostic scoring system for chronic myeloid leukemia in blast phase <p>Leukemia, Published online: 19 February 2026; <a href="https://www.nature.com/articles/s41375-026-02875-9">doi:10.1038/s41375-026-02875-9</a></p>Development of a prognostic scoring system for chronic myeloid leukemia in blast phase Leukemia Journal February 19, 2026 Original source
Repression of <i>miR-29</i> via MYC leads to increased CD40 signaling in transformed follicular lymphoma <p>Leukemia, Published online: 19 February 2026; <a href="https://www.nature.com/articles/s41375-026-02868-8">doi:10.1038/s41375-026-02868-8</a></p>Repression of <i>miR-29</i> via MYC leads to increased CD40 signaling in transformed follicular lymphoma Leukemia Journal February 19, 2026 Original source
Prof. Bayard Delafield Clarkson. 99 years of leukaemia research 15 July, 1926 to 30 December, 2025 <p>Leukemia, Published online: 19 February 2026; <a href="https://www.nature.com/articles/s41375-026-02881-x">doi:10.1038/s41375-026-02881-x</a></p>Prof. Bayard Delafield Clarkson. 99 years of leukaemia research 15 July, 1926 to 30 December, 2025 Leukemia Journal February 19, 2026 Original source
Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775 Background <p>In Study 309/KEYNOTE-775 (NCT03517449), lenvatinib+pembrolizumab versus chemotherapy significantly improved progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in advanced endometrial cancer (EC). We report 5-year follow-up results.</p> Methods <p>Participants had advanced/recurrent/metastatic EC with progressive disease after one prior platinum-based chemotherapy regimen, measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), and no… Journal for ImmunoTherapy of Cancer February 19, 2026 Original source
CSF proteomics identifies ADGRG1 as a predictive biomarker of intrathecal immune checkpoint inhibitor response in leptomeningeal metastasis Background <p>Leptomeningeal metastasis (LM) is a fatal complication of advanced cancer with limited therapeutic options and poor prognosis. Immune checkpoint inhibitors (ICIs) have shown promise in systemic disease, but intrathecal ICIs efficacy and immunological impact in LM remain unclear. Cerebrospinal fluid (CSF) proteomics may provide a unique window into the CNS immune microenvironment and enable response prediction.</p> Methods <p>We enrolled… Journal for ImmunoTherapy of Cancer February 19, 2026 Original source